A prognostic index predicting survival in transformed Waldenström macroglobulinemia.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
aheadofprint:
12
11
2020
received:
10
06
2020
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
28
5
2021
Statut:
epublish
Résumé
Histological transformation into diffuse large B-cell lymphoma is a rare complication in patients with Waldenström macroglobulinemia (WM) usually associated with a poor prognosis. The objective of this study was to develop and validate a prognostic index for survival in transformed WM patients. Through this multicenter, international collaborative effort, we developed a scoring system based on data from 133 patients with transformed WM who were evaluated between 1995 and 2016 (training cohort). Univariate and multivariate analyses were used to propose a prognostic index with 2-year survival after transformation as an end-point. For external validation, a data set of 67 patients was used to evaluate the performance of the model (validation cohort). By multivariate analysis, three adverse covariates were identified as independent predictors of 2-year survival after transformation: elevated serum LDH (2 points), platelet count < 100 x 109/L (1 point) and any previous treatment for WM (1 point). Three risk groups were defined: low-risk (0-1 point, 24% of patients), intermediate-risk (2-3 points, 59%, hazard ratio (HR) = 3.4) and high-risk (4 points, 17%, HR = 7.5). Two-year survival rates were 81%, 47%, and 21%, respectively (P < 0.0001). This model appeared to be a better discriminant than the International Prognostic Index (IPI) and the revised IPI (R-IPI). We validated this model in an independent cohort. This easy-to-compute scoring index is a robust tool that may allow identification of groups of transformed WM patients with different outcomes and could be used for improving the development of risk-adapted treatment strategies.
Identifiants
pubmed: 33179472
doi: 10.3324/haematol.2020.262899
pmc: PMC8561274
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2940-2946Références
Clin Cancer Res. 2016 Jun 1;22(11):2755-64
pubmed: 26792260
Am J Hematol. 2016 Oct;91(10):1032-5
pubmed: 27415417
Am J Hematol. 2020 Mar;95(3):274-281
pubmed: 31814157
Blood. 2007 Mar 1;109(5):1857-61
pubmed: 17105812
J Clin Oncol. 2013 Jan 20;31(3):301-7
pubmed: 23233721
J Clin Oncol. 2000 Nov 15;18(22):3782-93
pubmed: 11078491
N Engl J Med. 2012 Aug 30;367(9):826-33
pubmed: 22931316
Clin Cancer Res. 2017 May 1;23(9):2232-2244
pubmed: 27923841
Leuk Lymphoma. 2020 Feb;61(2):465-468
pubmed: 31544563
Br J Haematol. 2019 May;185(4):767-770
pubmed: 30338525
Leukemia. 2019 Nov;33(11):2654-2661
pubmed: 31118465
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Br J Haematol. 2017 Nov;179(3):439-448
pubmed: 28770576
Blood. 2013 Mar 14;121(11):2051-8
pubmed: 23321251
J Clin Oncol. 2006 May 20;24(15):2343-51
pubmed: 16710033
Semin Oncol. 2003 Apr;30(2):110-5
pubmed: 12720118
Blood. 2008 Jan 15;111(2):558-65
pubmed: 17962512
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Blood. 2004 Sep 1;104(5):1258-65
pubmed: 15126323
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Br J Haematol. 2018 Feb;180(3):374-380
pubmed: 29181840
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Br J Haematol. 2017 Sep;178(5):699-708
pubmed: 28782811
Blood. 2018 Jun 21;131(25):2761-2772
pubmed: 29692342
J Clin Oncol. 2018 Oct 12;:JCO1800138
pubmed: 30312133
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Blood. 2009 Apr 30;113(18):4163-70
pubmed: 19196866
Ann Hematol. 2017 Jan;96(1):1-8
pubmed: 27641425